Ilan Ziv, MD
Co-Founder, CEO and Chief Scientist
Ilan is a Senior Neurologist and Staff Member of the Rabin Medical Center. He is an Associate Professor of Neurology, the Tel-Aviv University. Ilan is a co-founder of Aposense, and the Chief Scientist of the Company. He is the Inventor of the Aposense Technology and all related products. Ilan has been involved in the field of apoptosis for more than two decades, with emphasis on the clinical applications of regulated cell death. Dr. Ziv is also a member of the Editorial Board of Apoptosis Journal.
Hagit Grimberg, Ph.D
Dr. Grimberg has been with Aposense for the past 14 years and has a strong background in innovation, research and new product development, driving product development as early as from the idea stage. Dr. Grimberg is responsible for leading Aposense’s therapeutic R&D projects through all development stages. Prior to her current position Dr. Grimberg served as Project Manager at Aposense. Dr. Grimberg obtained an M.Sc in Biochemistry from the Ben-Gurion University and a Ph.D in Physiology & Pharmacology from the Tel Aviv University. Dr. Grimberg has published several articles in leading journals and was awarded with numerous patents.
CFO & VP BD
Yuval has a master degree in business from Tel Aviv University, holds a wide scope of knowledge and experience in the financial and pharma market.
VP finance & COO
Ms. Genis began her career at Ernst & Young, where she was a manager and served 4 years. Ms. Genis was responsible for privately held and public listed clients (mainly NASDAQ) in the technology and communication sectors. Prior joining Aposense, Ms. Genis was a controller in Radview Software Ltd. (NASDAQ public traded company) for 1.5 years. Ms. Genis works at Aposense since 2008 and took part in Aposense's successful IPO on the TASE in 2010. Ms. Genis is a Certified Public Accountant (CPA) and holds a BA in Accounting from the College of Management in Tel-Aviv.